Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts assign Immuneering a consensus recommendation of Moderate Buy from seven analysts (1 sell, 5 buy, 1 strong buy) with an average 12‑month price target of $16.50.
• Shares opened at $5.57 with a market cap of $360.1M and a negative P/E (-4.04); the company reported quarterly EPS of -$0.18 (beating estimates of -$0.31) while analysts expect fiscal‑year EPS of -1.86.
• Immuneering is a clinical‑stage biopharma using an AI-driven RABIT platform to design small‑molecule and peptide therapies, and its lead program, IRX‑2, is in Phase 2 trials for painful diabetic peripheral neuropathy.

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $16.50.

Several brokerages have recently commented on IMRX. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 target price on shares of Immuneering in a report on Monday, March 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immuneering in a report on Friday, March 27th. Finally, Wall Street Zen downgraded Immuneering from a "hold" rating to a "sell" rating in a report on Saturday, April 11th.

Institutional Investors Weigh In On Immuneering

Hedge funds have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in shares of Immuneering during the first quarter valued at $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Immuneering during the fourth quarter valued at $33,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Immuneering during the third quarter valued at $35,000. Future Financial Wealth Managment LLC purchased a new stake in shares of Immuneering during the third quarter valued at $35,000. Finally, SummitTX Capital L.P. purchased a new stake in shares of Immuneering during the fourth quarter valued at $69,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

Immuneering Stock Down 3.1%

Shares of Immuneering stock opened at $5.57 on Friday. The firm has a market cap of $360.10 million, a price-to-earnings ratio of -4.04 and a beta of 0.43. The business has a fifty day simple moving average of $5.19 and a 200-day simple moving average of $5.79. Immuneering has a fifty-two week low of $1.10 and a fifty-two week high of $10.08.

Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings data on Friday, March 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.13. Analysts anticipate that Immuneering will post -1.86 earnings per share for the current fiscal year.

Immuneering Company Profile

Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.